Streetwise Reports
The Gold Report
The Energy Report
The Life Sciences Report
Streetwise Reports
The Gold Report
The Energy Report
more_reports

Streetwise ReportsThe Life Sciences Report

  • Menu
  • Streetwise Articles
    • Biotech/Pharmaceuticals
    • Medical Devices
    • Tools & Diagnostics
    • Management Q&A
  • Resources
    • Archives
    • Helpful Resources
    • Expert Profiles
      • Analysts
      • Newsletter Writers
      • Sector Experts
    • NASDAQ News
    • Directories
      • Alliance for Regenerative Medicine
      • Neurotechnology Industry Organization
  • Sponsors
    • Biotechnology/Pharmaceuticals
      • DURECT Corp.
      • Inovio Pharmaceuticals Inc.
      • ProMIS Neurosciences Inc.
      • RepliCel Life Sciences Inc.
      • Resverlogix Corp.
      • RXi Pharmaceuticals Corp.
      • Stellar Biotechnologies Inc.
      • Sunesis Pharmaceuticals Inc.
    • Life Sciences Tools & Diagnostics
      • 3D Signatures Inc.
    • Medical Devices
      • 3D Signatures Inc.
      • Viveve Medical Inc.
    • Regenerative Medicine
      • Regeneus Ltd.
      • RepliCel Life Sciences Inc.

  • Summit Announces Key Appointments to Strengthen Research and Development Team

  • Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD

  • EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate

  • Arbutus Presents HBV Drug Combination Studies at ICAR

  • Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results

  • Kraig Biocraft Laboratories Delivers First Dragon Silk Fiber Samples to US Army

  • Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress

  • Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting

  • Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care

  • Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress

Notable Quotes

"INO continues to advance multiple immunotherapy studies forward, which should provide incremental catalysts for the stock as data emerges." ❭
– Jason McCarthy, Maxim Group
"Based on RXI's new checkpoint inhibitors and the potential for multiple partnering deals, we are maintaining our Buy recommendation." ❭
– Keith Markey, Griffin Securities
"We continue to be optimistic about DRRX's story." ❭
– Grant Zeng, Zacks Investment Research, Zacks Small-Cap Research
"We initiate with an Outperform on VIVE." ❭
– Josh Jennings, Cowen & Co.
"RGS' strategy is to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development." ❭
– Dennis Hulme, Edison Investment Research

More Experts

"RVX remains gravely undervalued at the current share price." ❭
– Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research
"RXII developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds." ❭
– Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research
"We continue to be buyers of VIVE following its seventh consecutive quarter of double-digit revenue growth driven by a successful launch of the U.S. commercialization coupled with reaffirmed guidance." ❭
– Anthony Vendetti, Maxim Group
"We see the main value-creating events as initiation of INO's Phase III in cervical dysplasia and data in HIV and Zika later this year." ❭
– Charles Duncan, Piper Jaffray & Co.
"We see the deal with DRRX and Sandoz AG as relatively heavily front loaded and are encouraged by this large pharma validation." ❭
– Francois Brisebois, Laidlaw & Company
  • Subscribe
  • About
  • Disclaimer
  • Contact
  • Sponsorship
  • Syndication
  • Careers
  • Policies
FacebookTwitterEmailRSS FeedPrint ThisGoogle+Seeking Alpha

© 2017 Streetwise Reports. All rights reserved.

Streetwise Reports is registered with the U.S. Patent and Trademark Office.

envelope icon Get our newsletter free

A valid email address is required to subscribe
✖
Sign up